These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 29481571)

  • 1. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
    Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
    PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
    Solit DB; Osman I; Polsky D; Panageas KS; Daud A; Goydos JS; Teitcher J; Wolchok JD; Germino FJ; Krown SE; Coit D; Rosen N; Chapman PB
    Clin Cancer Res; 2008 Dec; 14(24):8302-7. PubMed ID: 19088048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.
    Banerji U; Affolter A; Judson I; Marais R; Workman P
    Mol Cancer Ther; 2008 Apr; 7(4):737-9. PubMed ID: 18375819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.
    Zhang T; Li Y; Zhu Z; Gu M; Newman B; Sun D
    Mol Pharm; 2010 Oct; 7(5):1576-84. PubMed ID: 20669973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
    Smyth T; Paraiso KHT; Hearn K; Rodriguez-Lopez AM; Munck JM; Haarberg HE; Sondak VK; Thompson NT; Azab M; Lyons JF; Smalley KSM; Wallis NG
    Mol Cancer Ther; 2014 Dec; 13(12):2793-2804. PubMed ID: 25349308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
    Abdel-Wahab O; Klimek VM; Gaskell AA; Viale A; Cheng D; Kim E; Rampal R; Bluth M; Harding JJ; Callahan MK; Merghoub T; Berger MF; Solit DB; Rosen N; Levine RL; Chapman PB
    Cancer Discov; 2014 May; 4(5):538-45. PubMed ID: 24589925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
    Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
    J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
    da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
    Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
    Koya RC; Mok S; Otte N; Blacketor KJ; Comin-Anduix B; Tumeh PC; Minasyan A; Graham NA; Graeber TG; Chodon T; Ribas A
    Cancer Res; 2012 Aug; 72(16):3928-37. PubMed ID: 22693252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.
    Beloueche-Babari M; Arunan V; Jackson LE; Perusinghe N; Sharp SY; Workman P; Leach MO
    Oncotarget; 2010 Jul; 1(3):185-97. PubMed ID: 21037799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
    Burger AM; Fiebig HH; Stinson SF; Sausville EA
    Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.